Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10452509rdf:typepubmed:Citationlld:pubmed
pubmed-article:10452509lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:10452509lifeskim:mentionsumls-concept:C0040132lld:lifeskim
pubmed-article:10452509lifeskim:mentionsumls-concept:C0025148lld:lifeskim
pubmed-article:10452509lifeskim:mentionsumls-concept:C0001629lld:lifeskim
pubmed-article:10452509lifeskim:mentionsumls-concept:C1550278lld:lifeskim
pubmed-article:10452509lifeskim:mentionsumls-concept:C0332152lld:lifeskim
pubmed-article:10452509lifeskim:mentionsumls-concept:C0277558lld:lifeskim
pubmed-article:10452509lifeskim:mentionsumls-concept:C0035363lld:lifeskim
pubmed-article:10452509pubmed:issue8lld:pubmed
pubmed-article:10452509pubmed:dateCreated1999-9-3lld:pubmed
pubmed-article:10452509pubmed:abstractTextThirty-eight patients (25 women, 13 men; mean age, 57.8 [32 to 91]) showing one or more medullary thyroid microcarcinomas (ie, < 1 cm), with no prior MEN II or medullary thyroid carcinoma history in their family, were reviewed. Follow-up was available for 29 patients (mean, 53.6 months [1 to 147]). 21 patients (72.4%) are alive and free of disease, four patients (13.8%) died during follow-up without disease, 2 patients are alive with disease (local recurrence and persistent hypercalcitoninemia) after 80 and 99 months, respectively, and 2 patients died of disease after 24 and 46 months. Most tumors were incidental pathological findings (19 of 38) or were discovered by systematic blood calcitonin measurement for a nodular thyroid disease (15 of 38). Only the four patients who had an unfavorable outcome were symptomatic cases (palpable micro-MTC, diarrhea, cervical lymph node metastasis and pulmonary metastatic disease). The two patients with metastatic disease at diagnosis died during follow-up. In univariate analysis, a symptomatic medullary thyroid carcinoma was a strong predictor of an unfavourable outcome (p < .00008), as were the preoperative calcitonin level (P = .007) and an elevated postoperative calcitonin level (P = .004). Among 30 histopathological criteria, only the presence of amyloid correlated with an unfavorable outcome (P = .018).lld:pubmed
pubmed-article:10452509pubmed:languageenglld:pubmed
pubmed-article:10452509pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10452509pubmed:citationSubsetIMlld:pubmed
pubmed-article:10452509pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10452509pubmed:statusMEDLINElld:pubmed
pubmed-article:10452509pubmed:monthAuglld:pubmed
pubmed-article:10452509pubmed:issn0046-8177lld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:PaterJJlld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:FrantSSlld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:GuerisJJlld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:BigorgneJ CJClld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:CaillouBBlld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:Saint-AndreJ...lld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:Lecomte-Houck...lld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:ViennetGGlld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:Dutrieux-Berg...lld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:DupreFFlld:pubmed
pubmed-article:10452509pubmed:authorpubmed-author:GuyétantSSlld:pubmed
pubmed-article:10452509pubmed:issnTypePrintlld:pubmed
pubmed-article:10452509pubmed:volume30lld:pubmed
pubmed-article:10452509pubmed:ownerNLMlld:pubmed
pubmed-article:10452509pubmed:authorsCompleteYlld:pubmed
pubmed-article:10452509pubmed:pagination957-63lld:pubmed
pubmed-article:10452509pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:meshHeadingpubmed-meshheading:10452509...lld:pubmed
pubmed-article:10452509pubmed:year1999lld:pubmed
pubmed-article:10452509pubmed:articleTitleMedullary thyroid microcarcinoma: a clinicopathologic retrospective study of 38 patients with no prior familial disease.lld:pubmed
pubmed-article:10452509pubmed:affiliationDepartment of Pathology, Médecine C, Centre Hospitalier Universitaire, Angers, France.lld:pubmed
pubmed-article:10452509pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10452509lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10452509lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10452509lld:pubmed